 Martin Hertl
Concepts (324)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 28 | 2018 | 112 | 5.530 |
Why?
| | Liver | 13 | 2019 | 213 | 2.360 |
Why?
| | Kidney Transplantation | 10 | 2021 | 153 | 2.000 |
Why?
| | Living Donors | 9 | 2011 | 17 | 1.530 |
Why?
| | Portal Vein | 7 | 2018 | 50 | 1.450 |
Why?
| | Hepatectomy | 7 | 2018 | 68 | 1.350 |
Why?
| | Carcinoma, Hepatocellular | 6 | 2021 | 44 | 1.310 |
Why?
| | Liver Neoplasms | 6 | 2021 | 122 | 1.210 |
Why?
| | Galactosyltransferases | 3 | 2013 | 3 | 0.870 |
Why?
| | Liver Failure, Acute | 4 | 2018 | 5 | 0.870 |
Why?
| | Gallstones | 1 | 2021 | 8 | 0.850 |
Why?
| | Pancreatitis | 1 | 2021 | 24 | 0.840 |
Why?
| | Transplantation, Heterologous | 3 | 2016 | 25 | 0.720 |
Why?
| | Hepatomegaly | 1 | 2018 | 6 | 0.690 |
Why?
| | Humans | 58 | 2022 | 32988 | 0.670 |
Why?
| | Organ Preservation | 3 | 2011 | 9 | 0.660 |
Why?
| | Swine | 9 | 2018 | 116 | 0.660 |
Why?
| | Tissue Donors | 3 | 2021 | 85 | 0.610 |
Why?
| | Liver Regeneration | 4 | 2017 | 29 | 0.610 |
Why?
| | Kidney Failure, Chronic | 7 | 2020 | 188 | 0.580 |
Why?
| | Male | 39 | 2021 | 17726 | 0.530 |
Why?
| | Retrospective Studies | 16 | 2022 | 3835 | 0.510 |
Why?
| | Neuroendocrine Tumors | 3 | 2019 | 51 | 0.500 |
Why?
| | Middle Aged | 29 | 2020 | 11219 | 0.500 |
Why?
| | Bile Ducts | 2 | 2011 | 14 | 0.480 |
Why?
| | BK Virus | 1 | 2013 | 13 | 0.470 |
Why?
| | Constriction, Pathologic | 2 | 2019 | 43 | 0.470 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2013 | 17 | 0.460 |
Why?
| | Perfusion | 2 | 2011 | 24 | 0.450 |
Why?
| | Kidney Neoplasms | 1 | 2013 | 77 | 0.440 |
Why?
| | Animals | 15 | 2021 | 5371 | 0.440 |
Why?
| | Hypertension, Malignant | 1 | 2012 | 2 | 0.440 |
Why?
| | Protein S Deficiency | 1 | 2011 | 2 | 0.430 |
Why?
| | Organ Transplantation | 2 | 2021 | 43 | 0.410 |
Why?
| | Hypercholesterolemia | 1 | 2011 | 39 | 0.410 |
Why?
| | Arteriovenous Shunt, Surgical | 2 | 2022 | 23 | 0.410 |
Why?
| | Mesentery | 1 | 2011 | 5 | 0.410 |
Why?
| | Peritoneal Neoplasms | 1 | 2011 | 6 | 0.410 |
Why?
| | Ligation | 4 | 2018 | 38 | 0.410 |
Why?
| | Carcinoid Tumor | 1 | 2011 | 21 | 0.400 |
Why?
| | Female | 29 | 2021 | 18423 | 0.400 |
Why?
| | Pancreas | 2 | 2021 | 39 | 0.380 |
Why?
| | Decision Support Techniques | 1 | 2010 | 57 | 0.380 |
Why?
| | Kidney | 4 | 2021 | 219 | 0.380 |
Why?
| | Intestines | 1 | 2011 | 115 | 0.380 |
Why?
| | Endothelial Cells | 1 | 2010 | 69 | 0.370 |
Why?
| | Adrenal Cortex Neoplasms | 2 | 2020 | 13 | 0.370 |
Why?
| | Adrenocortical Carcinoma | 2 | 2020 | 12 | 0.370 |
Why?
| | Postoperative Complications | 9 | 2022 | 1117 | 0.350 |
Why?
| | Pancreatic Neoplasms | 3 | 2019 | 176 | 0.340 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2008 | 9 | 0.340 |
Why?
| | Bile Duct Neoplasms | 2 | 2005 | 14 | 0.330 |
Why?
| | Food Hypersensitivity | 1 | 2009 | 57 | 0.330 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2008 | 1 | 0.330 |
Why?
| | Informed Consent | 2 | 2005 | 25 | 0.320 |
Why?
| | Tissue and Organ Harvesting | 3 | 2004 | 23 | 0.320 |
Why?
| | Gynecomastia | 1 | 2007 | 1 | 0.320 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2007 | 15 | 0.310 |
Why?
| | Treatment Outcome | 14 | 2022 | 4036 | 0.310 |
Why?
| | Incidental Findings | 1 | 2007 | 20 | 0.310 |
Why?
| | Hepatitis C | 1 | 2008 | 70 | 0.310 |
Why?
| | Breast Neoplasms | 2 | 2011 | 435 | 0.300 |
Why?
| | Neoplasm Staging | 4 | 2019 | 457 | 0.300 |
Why?
| | Graft Survival | 8 | 2016 | 110 | 0.290 |
Why?
| | Biliary Tract Diseases | 2 | 2019 | 7 | 0.290 |
Why?
| | Survival Rate | 6 | 2020 | 443 | 0.290 |
Why?
| | Tissue and Organ Procurement | 2 | 2003 | 37 | 0.290 |
Why?
| | Coccidioides | 1 | 2006 | 3 | 0.290 |
Why?
| | Coccidioidomycosis | 1 | 2006 | 8 | 0.290 |
Why?
| | Time Factors | 7 | 2022 | 1873 | 0.280 |
Why?
| | Registries | 1 | 2007 | 226 | 0.270 |
Why?
| | Liver Diseases | 2 | 2017 | 47 | 0.270 |
Why?
| | Directed Tissue Donation | 1 | 2005 | 1 | 0.270 |
Why?
| | Donor Selection | 1 | 2005 | 1 | 0.270 |
Why?
| | Physician-Patient Relations | 1 | 2005 | 47 | 0.260 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 2 | 2021 | 11 | 0.250 |
Why?
| | Adult | 13 | 2020 | 9848 | 0.250 |
Why?
| | Hepatitis B, Chronic | 1 | 2003 | 7 | 0.250 |
Why?
| | Postoperative Hemorrhage | 2 | 2014 | 29 | 0.240 |
Why?
| | Biliary Tract Surgical Procedures | 2 | 2019 | 4 | 0.240 |
Why?
| | Communication | 1 | 2005 | 133 | 0.240 |
Why?
| | Papio hamadryas | 2 | 2013 | 2 | 0.240 |
Why?
| | Swine, Miniature | 2 | 2013 | 9 | 0.240 |
Why?
| | Liver Function Tests | 4 | 2015 | 29 | 0.240 |
Why?
| | Venous Thrombosis | 2 | 2019 | 55 | 0.230 |
Why?
| | Incidence | 3 | 2021 | 840 | 0.230 |
Why?
| | Gastroparesis | 1 | 2022 | 3 | 0.220 |
Why?
| | Arteriovenous Fistula | 1 | 2022 | 12 | 0.220 |
Why?
| | Aneurysm | 1 | 2022 | 20 | 0.220 |
Why?
| | Random Allocation | 3 | 2018 | 162 | 0.220 |
Why?
| | Pancreaticoduodenectomy | 1 | 2022 | 31 | 0.220 |
Why?
| | Urogenital Abnormalities | 1 | 2021 | 7 | 0.220 |
Why?
| | Pancreas Transplantation | 1 | 2021 | 17 | 0.210 |
Why?
| | Infertility, Female | 1 | 2021 | 23 | 0.210 |
Why?
| | Cholecystectomy | 1 | 2021 | 19 | 0.210 |
Why?
| | Hospitals, University | 1 | 2001 | 44 | 0.210 |
Why?
| | Specialization | 1 | 2001 | 22 | 0.210 |
Why?
| | Raffinose | 1 | 2001 | 2 | 0.210 |
Why?
| | Organ Preservation Solutions | 1 | 2001 | 2 | 0.210 |
Why?
| | Ursodeoxycholic Acid | 1 | 2001 | 3 | 0.210 |
Why?
| | Glutathione | 1 | 2001 | 31 | 0.210 |
Why?
| | Allopurinol | 1 | 2001 | 6 | 0.210 |
Why?
| | Organ Size | 2 | 2018 | 119 | 0.210 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 29 | 0.210 |
Why?
| | Adenosine | 1 | 2001 | 16 | 0.210 |
Why?
| | Immunoglobulin G | 2 | 2013 | 149 | 0.210 |
Why?
| | Graft vs Host Disease | 1 | 2021 | 60 | 0.210 |
Why?
| | Transplant Recipients | 1 | 2021 | 26 | 0.200 |
Why?
| | Bone Marrow Transplantation | 2 | 2013 | 41 | 0.200 |
Why?
| | Ultrasonography | 3 | 2018 | 215 | 0.200 |
Why?
| | Antineoplastic Agents | 2 | 2021 | 244 | 0.200 |
Why?
| | Follow-Up Studies | 5 | 2020 | 2053 | 0.200 |
Why?
| | Surgical Instruments | 1 | 2020 | 30 | 0.200 |
Why?
| | Renal Dialysis | 4 | 2022 | 132 | 0.200 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2021 | 126 | 0.200 |
Why?
| | Insulin | 1 | 2001 | 117 | 0.190 |
Why?
| | Hepatic Veins | 2 | 2018 | 10 | 0.190 |
Why?
| | Adrenalectomy | 1 | 2019 | 5 | 0.190 |
Why?
| | Health Care Costs | 1 | 2020 | 83 | 0.190 |
Why?
| | Jejunostomy | 1 | 2019 | 9 | 0.190 |
Why?
| | Prognosis | 4 | 2020 | 1011 | 0.190 |
Why?
| | Pancreatectomy | 1 | 2019 | 16 | 0.180 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2019 | 90 | 0.180 |
Why?
| | Suture Techniques | 1 | 2020 | 149 | 0.180 |
Why?
| | Breast Implants | 3 | 2011 | 8 | 0.180 |
Why?
| | Cholagogues and Choleretics | 1 | 1999 | 1 | 0.180 |
Why?
| | Taurochenodeoxycholic Acid | 1 | 1999 | 2 | 0.180 |
Why?
| | Reperfusion Injury | 1 | 1999 | 7 | 0.180 |
Why?
| | Abdominal Neoplasms | 1 | 2019 | 12 | 0.180 |
Why?
| | Heat Stroke | 1 | 2018 | 1 | 0.170 |
Why?
| | Intestinal Neoplasms | 1 | 2018 | 13 | 0.170 |
Why?
| | Digestive System Surgical Procedures | 1 | 2018 | 27 | 0.170 |
Why?
| | Liver Failure | 1 | 2018 | 13 | 0.170 |
Why?
| | Patient Compliance | 1 | 2020 | 200 | 0.170 |
Why?
| | Hospitalization | 1 | 2021 | 367 | 0.170 |
Why?
| | Papio | 3 | 2016 | 12 | 0.170 |
Why?
| | Pulmonary Embolism | 1 | 2019 | 58 | 0.170 |
Why?
| | Stomach Neoplasms | 1 | 2018 | 41 | 0.170 |
Why?
| | Child, Preschool | 2 | 2013 | 798 | 0.170 |
Why?
| | Venous Thromboembolism | 1 | 2019 | 58 | 0.160 |
Why?
| | Hypertrophy | 1 | 2017 | 25 | 0.160 |
Why?
| | Neovascularization, Physiologic | 1 | 2017 | 30 | 0.160 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 86 | 0.160 |
Why?
| | Vascular Patency | 4 | 2022 | 31 | 0.150 |
Why?
| | Aged | 11 | 2020 | 10542 | 0.150 |
Why?
| | Prostatic Neoplasms | 1 | 2017 | 125 | 0.140 |
Why?
| | Gene Knockout Techniques | 2 | 2013 | 12 | 0.140 |
Why?
| | Patient Selection | 4 | 2019 | 261 | 0.140 |
Why?
| | Thrombocytopenia | 2 | 2014 | 31 | 0.140 |
Why?
| | Graft Occlusion, Vascular | 2 | 2022 | 29 | 0.140 |
Why?
| | Tobacco Use Disorder | 1 | 2015 | 20 | 0.140 |
Why?
| | Kaplan-Meier Estimate | 2 | 2019 | 216 | 0.140 |
Why?
| | Jaundice, Obstructive | 1 | 2015 | 1 | 0.140 |
Why?
| | Cysts | 1 | 2015 | 21 | 0.130 |
Why?
| | Biopsy | 2 | 2013 | 277 | 0.130 |
Why?
| | Disease Models, Animal | 1 | 2018 | 844 | 0.130 |
Why?
| | Graft Rejection | 4 | 2020 | 87 | 0.130 |
Why?
| | Liver Cirrhosis | 1 | 2014 | 61 | 0.130 |
Why?
| | Antibodies, Heterophile | 1 | 2013 | 1 | 0.120 |
Why?
| | Heterografts | 1 | 2013 | 17 | 0.120 |
Why?
| | Heart Transplantation | 1 | 2014 | 51 | 0.120 |
Why?
| | Heart-Assist Devices | 1 | 2014 | 32 | 0.120 |
Why?
| | Creatinine | 1 | 2013 | 59 | 0.120 |
Why?
| | Hematoma | 1 | 2013 | 25 | 0.120 |
Why?
| | Immunosuppressive Agents | 3 | 2020 | 166 | 0.120 |
Why?
| | Ureterostomy | 1 | 2012 | 1 | 0.110 |
Why?
| | Cystostomy | 1 | 2012 | 4 | 0.110 |
Why?
| | Polytetrafluoroethylene | 2 | 2011 | 8 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 3 | 2015 | 1315 | 0.110 |
Why?
| | Ureter | 1 | 2012 | 27 | 0.110 |
Why?
| | Blood Vessel Prosthesis | 2 | 2011 | 27 | 0.110 |
Why?
| | Protein S | 1 | 2011 | 2 | 0.110 |
Why?
| | Hepatic Encephalopathy | 1 | 2012 | 7 | 0.110 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 120 | 0.110 |
Why?
| | Warm Ischemia | 1 | 2011 | 2 | 0.110 |
Why?
| | Bile | 1 | 2011 | 6 | 0.110 |
Why?
| | Intracranial Hypertension | 1 | 2012 | 14 | 0.110 |
Why?
| | Intracranial Pressure | 1 | 2012 | 26 | 0.110 |
Why?
| | Bilirubin | 1 | 2011 | 11 | 0.110 |
Why?
| | Alkaline Phosphatase | 1 | 2011 | 18 | 0.110 |
Why?
| | Breast Implantation | 1 | 2011 | 4 | 0.110 |
Why?
| | Hepatitis, Autoimmune | 1 | 2011 | 9 | 0.110 |
Why?
| | Databases, Factual | 3 | 2019 | 393 | 0.110 |
Why?
| | Monitoring, Intraoperative | 1 | 2012 | 43 | 0.110 |
Why?
| | Hemodynamics | 1 | 2011 | 100 | 0.100 |
Why?
| | Mastectomy | 1 | 2011 | 34 | 0.100 |
Why?
| | Endoscopy, Digestive System | 1 | 2011 | 10 | 0.100 |
Why?
| | Intestinal Obstruction | 1 | 2011 | 15 | 0.100 |
Why?
| | Waiting Lists | 2 | 2014 | 18 | 0.100 |
Why?
| | Energy Metabolism | 1 | 2011 | 82 | 0.100 |
Why?
| | Oxygen | 1 | 2011 | 105 | 0.100 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2011 | 29 | 0.100 |
Why?
| | Complement C3a | 1 | 2010 | 3 | 0.100 |
Why?
| | Complement Activation | 1 | 2010 | 15 | 0.100 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2010 | 33 | 0.100 |
Why?
| | Immunoglobulin M | 1 | 2010 | 23 | 0.100 |
Why?
| | End Stage Liver Disease | 1 | 2010 | 18 | 0.100 |
Why?
| | Transplantation, Autologous | 1 | 2011 | 221 | 0.100 |
Why?
| | Tissue Engineering | 1 | 2010 | 50 | 0.090 |
Why?
| | Rats | 3 | 2016 | 972 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 2 | 2015 | 899 | 0.090 |
Why?
| | Anaphylaxis | 1 | 2009 | 11 | 0.090 |
Why?
| | Fatal Outcome | 1 | 2009 | 76 | 0.090 |
Why?
| | Nephrectomy | 1 | 2009 | 43 | 0.090 |
Why?
| | Survival Analysis | 3 | 2018 | 372 | 0.090 |
Why?
| | Risk Factors | 3 | 2022 | 2762 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2010 | 244 | 0.090 |
Why?
| | Models, Animal | 2 | 2016 | 147 | 0.090 |
Why?
| | Hemophilia A | 1 | 2008 | 43 | 0.080 |
Why?
| | Young Adult | 2 | 2020 | 2287 | 0.080 |
Why?
| | Transplantation Chimera | 1 | 2008 | 3 | 0.080 |
Why?
| | Transplantation Tolerance | 1 | 2008 | 4 | 0.080 |
Why?
| | Cadaver | 1 | 2009 | 366 | 0.080 |
Why?
| | United States | 3 | 2020 | 2632 | 0.080 |
Why?
| | Multivariate Analysis | 2 | 2019 | 386 | 0.080 |
Why?
| | Colonoscopy | 1 | 2008 | 90 | 0.080 |
Why?
| | Rats, Wistar | 2 | 2017 | 64 | 0.080 |
Why?
| | Reoperation | 1 | 2012 | 970 | 0.080 |
Why?
| | New England | 1 | 2006 | 4 | 0.070 |
Why?
| | Cholangitis, Sclerosing | 1 | 2006 | 4 | 0.070 |
Why?
| | Hepatoblastoma | 1 | 2005 | 1 | 0.070 |
Why?
| | Blood Coagulation Factors | 2 | 2016 | 20 | 0.070 |
Why?
| | Hemangioendothelioma, Epithelioid | 1 | 2005 | 3 | 0.070 |
Why?
| | Cystic Duct | 1 | 2005 | 1 | 0.070 |
Why?
| | Cholangiocarcinoma | 1 | 2005 | 13 | 0.070 |
Why?
| | Coercion | 1 | 2005 | 7 | 0.070 |
Why?
| | Cholestasis | 1 | 2005 | 9 | 0.070 |
Why?
| | Social Values | 1 | 2005 | 11 | 0.070 |
Why?
| | Interview, Psychological | 1 | 2005 | 45 | 0.070 |
Why?
| | Postoperative Period | 2 | 2019 | 298 | 0.070 |
Why?
| | Medical Oncology | 1 | 2005 | 37 | 0.070 |
Why?
| | Liver Circulation | 2 | 2017 | 7 | 0.060 |
Why?
| | Animals, Genetically Modified | 2 | 2014 | 18 | 0.060 |
Why?
| | Adenoma | 1 | 2005 | 63 | 0.060 |
Why?
| | Referral and Consultation | 1 | 2005 | 102 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 449 | 0.060 |
Why?
| | Anastomosis, Surgical | 2 | 2019 | 57 | 0.060 |
Why?
| | Contrast Media | 1 | 2004 | 148 | 0.060 |
Why?
| | Decision Making | 1 | 2005 | 239 | 0.060 |
Why?
| | Pancreatic Fistula | 1 | 2022 | 3 | 0.050 |
Why?
| | Steroids | 1 | 2022 | 31 | 0.050 |
Why?
| | Uterus | 1 | 2021 | 27 | 0.050 |
Why?
| | Hysterectomy | 1 | 2021 | 24 | 0.050 |
Why?
| | Naphthoquinones | 1 | 2021 | 6 | 0.050 |
Why?
| | Rats, Inbred Lew | 1 | 2001 | 13 | 0.050 |
Why?
| | Benzofurans | 1 | 2021 | 8 | 0.050 |
Why?
| | Aniline Compounds | 1 | 2021 | 41 | 0.050 |
Why?
| | Sulfonamides | 1 | 2021 | 60 | 0.050 |
Why?
| | In Vitro Techniques | 1 | 2001 | 244 | 0.050 |
Why?
| | Cost Savings | 1 | 2020 | 42 | 0.050 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 159 | 0.050 |
Why?
| | Mitotane | 1 | 2019 | 3 | 0.050 |
Why?
| | Quality Improvement | 1 | 2022 | 173 | 0.050 |
Why?
| | Diagnosis, Differential | 2 | 2013 | 462 | 0.050 |
Why?
| | Lymphatic Metastasis | 1 | 2020 | 101 | 0.050 |
Why?
| | Tumor Burden | 1 | 2019 | 38 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2019 | 228 | 0.040 |
Why?
| | Blood Coagulation Disorders | 1 | 2019 | 18 | 0.040 |
Why?
| | Serum Albumin | 1 | 2019 | 31 | 0.040 |
Why?
| | Cyclosporine | 1 | 1999 | 20 | 0.040 |
Why?
| | Operative Time | 1 | 2019 | 96 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 387 | 0.040 |
Why?
| | Prostate-Specific Antigen | 1 | 2017 | 19 | 0.040 |
Why?
| | Portal Pressure | 1 | 2017 | 6 | 0.040 |
Why?
| | Fungi | 1 | 1997 | 6 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 494 | 0.040 |
Why?
| | Adolescent | 2 | 2020 | 2687 | 0.040 |
Why?
| | Anticoagulants | 1 | 2019 | 153 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 378 | 0.040 |
Why?
| | Hyperplasia | 1 | 2017 | 25 | 0.040 |
Why?
| | Bacteria | 1 | 1997 | 82 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 388 | 0.040 |
Why?
| | Cell Hypoxia | 1 | 2016 | 17 | 0.040 |
Why?
| | Paecilomyces | 1 | 1995 | 3 | 0.040 |
Why?
| | Policy | 1 | 2015 | 11 | 0.040 |
Why?
| | Mice | 1 | 2021 | 1958 | 0.030 |
Why?
| | Mycoses | 1 | 1995 | 23 | 0.030 |
Why?
| | Brain | 1 | 2006 | 1752 | 0.030 |
Why?
| | Chicago | 1 | 2018 | 957 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2015 | 54 | 0.030 |
Why?
| | Blood Transfusion | 1 | 2014 | 70 | 0.030 |
Why?
| | Smoking | 1 | 2015 | 206 | 0.030 |
Why?
| | Risk Assessment | 1 | 2017 | 814 | 0.030 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2013 | 9 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2015 | 189 | 0.030 |
Why?
| | Cardiovascular Diseases | 1 | 2018 | 446 | 0.030 |
Why?
| | Immunity, Cellular | 1 | 2013 | 71 | 0.030 |
Why?
| | Stents | 1 | 2015 | 159 | 0.030 |
Why?
| | Prosthesis-Related Infections | 1 | 1995 | 217 | 0.030 |
Why?
| | Cohort Studies | 1 | 2018 | 2077 | 0.030 |
Why?
| | Massachusetts | 1 | 2011 | 24 | 0.030 |
Why?
| | Biocompatible Materials | 1 | 2011 | 122 | 0.020 |
Why?
| | Hepatocytes | 1 | 2010 | 12 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2010 | 91 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 5249 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2011 | 193 | 0.020 |
Why?
| | Angiography | 1 | 2009 | 58 | 0.020 |
Why?
| | Factor VIII | 1 | 2008 | 27 | 0.020 |
Why?
| | Blood Loss, Surgical | 1 | 2008 | 69 | 0.020 |
Why?
| | Hemorrhage | 1 | 2008 | 95 | 0.020 |
Why?
| | Hepatocyte Nuclear Factor 3-alpha | 1 | 2008 | 1 | 0.020 |
Why?
| | Transplantation Immunology | 1 | 2008 | 3 | 0.020 |
Why?
| | Histocompatibility Testing | 1 | 2008 | 6 | 0.020 |
Why?
| | Granzymes | 1 | 2008 | 8 | 0.020 |
Why?
| | Transplantation Conditioning | 1 | 2008 | 47 | 0.020 |
Why?
| | Hepatitis C, Chronic | 1 | 2008 | 81 | 0.020 |
Why?
| | Laparoscopy | 1 | 2009 | 193 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2008 | 229 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2008 | 376 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2008 | 297 | 0.020 |
Why?
| | Sodium Chloride | 2 | 1997 | 45 | 0.020 |
Why?
| | Vena Cava, Inferior | 1 | 2006 | 13 | 0.020 |
Why?
| | Prospective Studies | 1 | 2011 | 2002 | 0.020 |
Why?
| | Syndrome | 1 | 2005 | 101 | 0.020 |
Why?
| | Biliary Tract | 1 | 2004 | 3 | 0.020 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2004 | 4 | 0.020 |
Why?
| | Hepatic Artery | 1 | 2004 | 3 | 0.020 |
Why?
| | Magnetic Resonance Angiography | 1 | 2004 | 51 | 0.020 |
Why?
| | Preoperative Care | 1 | 2004 | 148 | 0.010 |
Why?
| | Imaging, Three-Dimensional | 1 | 2004 | 235 | 0.010 |
Why?
| | Forecasting | 1 | 2001 | 136 | 0.010 |
Why?
| | Silicone Elastomers | 1 | 1997 | 3 | 0.010 |
Why?
| | Culture Media | 1 | 1997 | 44 | 0.010 |
Why?
| | Rabbits | 1 | 1997 | 336 | 0.010 |
Why?
|
|
Hertl's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|